Why Local Expertise Matters When Expanding Clinical Programs into LATAM

Welcome back to the blog! If you are a biotech or pharmaceutical sponsor looking to scale your clinical trials globally, the Latin American market undoubtedly sits on your radar. With a large, diverse patient population, world-class principal investigators, and a growing infrastructure for clinical research, LATAM presents a massive opportunity to accelerate development timelines. However, expanding clinical programs into this region is far from straightforward. Entering the Latin American pharmaceutical market without the right partner can lead to costly delays, regulatory roadblocks, and immense frustration. In this blog post, we are going to break down the critical factors sponsors must consider when entering the region, and explore how specialized local execution makes all the difference. For an even deeper dive into this topic, make sure to check out our accompanying podcast episode featuring Daniel Zequeto in Daniel Zequeto, Founder & CEO at ODC Life Sciences, where we discuss the intricacies of conducting clinical trials across Brazil and Latin America.

The Hidden Costs of Entering LATAM Without the Right Partner

When global pharmaceutical companies and emerging biotech firms look at international expansion, they often underestimate the sheer complexity of operating in new geographic regions. Latin America is not a single, homogeneous market; it is a tapestry of distinct countries, each with its own regulatory bodies, cultural nuances, import-export laws, and healthcare systems. Treating the region as a monolith is one of the most dangerous mistakes a sponsor can make.

Without deep local knowledge, sponsors frequently encounter hidden costs that derail both budgets and timelines. For instance, import and export regulations regarding biological samples and investigational medicinal products vary wildly from country to country. A delay at customs can compromise the stability of temperature-sensitive drugs, resulting in wasted product and halted trial sites. Furthermore, bureaucratic hurdles can significantly extend approval timelines if a team is unfamiliar with the specific expectations of national regulatory agencies.

Beyond logistics, communication barriers and a lack of established relationships with local institutional review boards and ethics committees can stall a program before a single patient is enrolled. Partnering with organizations that possess boots-on-the-ground experience eliminates these friction points. Local experts already understand the bureaucratic landscape, have pre-existing relationships with key opinion leaders, and know how to navigate the subtle cultural differences that influence site engagement and patient retention. Ultimately, investing in local expertise upfront safeguards your program against the exorbitant costs of delay.

Navigating Clinical Development Across Brazil and Latin America

When discussing clinical research in Latin America, Brazil naturally takes center stage as the largest pharmaceutical market in the region. Brazil boasts a robust healthcare infrastructure, highly skilled medical professionals, and dense urban populations that are ideal for clinical trials. However, the regulatory environment governed by ANVISA (Agência Nacional de Vigilância Sanitária) comes with unique compliance requirements, strict timelines, and specific documentation standards that require meticulous attention to detail.

Navigating clinical development successfully across Brazil and the broader LATAM region requires a nuanced understanding of national health systems, public versus private hospital networks, and regional ethics committee structures. For example, while Brazil has a centralized ethical review system through CONEP (Comissão Nacional de Ética em Pesquisa) for specific areas like indigenous populations or vulnerable groups, standard studies require approval from both national and local institutional review boards. Knowing how to efficiently coordinate these submissions can shave months off a startup timeline.

Moreover, neighboring countries like Argentina, Colombia, Mexico, and Chile each offer their own strategic advantages and regulatory challenges. A successful multi-country trial in LATAM demands a harmonized operational strategy that respects local sovereignty while maintaining global data integrity. By leveraging regional insights, sponsors can select the right countries and sites for their specific protocols, ensuring optimal patient enrollment and high-quality data generation from day one.

Overcoming Challenges in Patient Recruitment and Early Access

One of the primary drivers for bringing clinical trials to Latin America is the region's vast and treatment-naive patient population. Many patients in LATAM face limited access to cutting-edge therapies through standard healthcare channels, making clinical trials an attractive, life-changing option. Yet, simply having a large patient pool does not automatically translate to rapid recruitment.

Patient recruitment and retention in LATAM come with their own set of hurdles. Geographic vastness, socioeconomic barriers, transportation challenges, and mistrust of the medical establishment can hinder engagement if not approached with cultural sensitivity. Local clinical teams understand how to build trust within communities, educate patients effectively about the clinical trial process, and design patient-centric support programs that reduce drop-out rates.

In addition to traditional clinical trials, early access programs and compassionate use frameworks play a vital role in the LATAM healthcare ecosystem. Patients and physicians are often eager to access innovative treatments before commercial availability. Managing early access programs requires navigating complex compassionate use regulations, import licenses, and ongoing safety monitoring. Doing this successfully requires robust local infrastructure that can handle the distribution and tracking of therapies outside of standard clinical trial pathways while maintaining absolute compliance with local health authorities.

Therapeutic Focus: Rare Diseases, Oncology, and Beyond

While Latin America supports a wide array of therapeutic indications, certain clinical specialties have seen exponential growth and success in the region. Rare diseases, oncology, hematology, nephrology, and neurology stand out as areas where LATAM offers exceptional value to global sponsors. Because rare disease patients are often scattered globally, finding concentrated pockets of diagnosed populations can be immensely difficult in North America or Europe. LATAM’s centralized specialized centers of excellence often treat large cohorts of patients with specific genetic disorders or rare oncological profiles.

Conducting trials in oncology and rare diseases demands a high level of clinical sophistication. Investigators in LATAM are frequently involved in global academic research networks and are accustomed to complex protocols, stringent data capture, and advanced biomarker testing. However, coordinating these sophisticated trials across multiple borders requires specialized logistics—such as cryogenic transport for cell and gene therapies or specialized central lab coordination.

Sponsors focusing on these complex therapeutic areas cannot afford to work with generic, one-size-fits-all operational models. They need specialized execution partners who understand the clinical pathways of rare disease patients, the intricacies of oncology endpoints, and the specific needs of specialized investigators. This level of specialization ensures that protocol deviations are minimized, data quality remains uncompromised, and vulnerable patient populations are treated with the highest standard of care.

The Power of Specialized Local Execution

At the end of the day, the success of a clinical trial in Latin America boils down to execution. Global strategy is important, but execution happens locally, site by site, patient by patient. This is why specialized local execution partners are becoming indispensable to biotech and pharmaceutical sponsors alike.

A specialized local partner brings agility, deep regional networks, and proactive problem-solving capabilities that large, monolithic contract research organizations sometimes lack. They act as an extension of the sponsor's team, translating global expectations into local operational realities. Whether it is negotiating budgets with clinical sites, managing local supply chains, or ensuring regulatory compliance with regional health authorities, having experts on the ground changes the trajectory of a trial.

Furthermore, local partners foster strong relationships with investigators and site staff. In clinical research, site relationships are everything. Sites that feel supported, valued, and well-resourced are far more likely to prioritize your protocol, engage proactively with patients, and deliver clean data on time. Investing in specialized local execution is not an added expense; it is a strategic multiplier that drives efficiency, reduces risk, and accelerates time-to-market for life-saving therapies.

Conclusion: Partnering for Success in LATAM

Expanding clinical programs into Latin America offers unprecedented opportunities for biotech and pharmaceutical companies to access diverse patient populations, collaborate with world-class investigators, and accelerate their global development pathways. However, as we have explored, the region's regulatory complexity, logistical hurdles, and cultural nuances mean that success is never guaranteed. Entering LATAM without the right strategy and local infrastructure can lead to costly delays and missed milestones. By prioritizing specialized local expertise, understanding regional regulatory environments, and implementing patient-centric recruitment strategies, sponsors can unlock the true potential of the Latin American market.

To learn more about mastering clinical development across Brazil and Latin America, be sure to listen to our full conversation with Daniel Zequeto. You can access the episode directly by visiting Daniel Zequeto, Founder & CEO at ODC Life Sciences, where we dive even deeper into the real-world challenges and solutions for clinical execution in LATAM. Thank you for reading, and stay tuned for more insights on global trial acceleration!